MDRNA Secures $7,250,000 Series D Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=8ec043f0-02bb-46a2-a9a5-40ac9cbb38cf&Preview=1 -
Date
3/23/2009 -
Company Name
MDRNA -
Mailing Address
3830 Monte Villa Parkway Bothell, WA 98021 -
Company Description
MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). We are building a broad, flexible and cutting-edge drug discovery platform based on the premise that no single RNAi technology or delivery approach can overcome the target specific and indication specific challenges of down regulating protein expression via a siRNA therapeutic. As a result, we have implemented a multi-faceted, multi-disciplinary and multi-technological approach to discovering novel and proprietary RNAi-based therapeutics we are confident will lead to clinical success. -
Website
http://www.mdrnainc.com -
Transaction Type
Venture Equity -
Transaction Amount
$7,250,000 -
Transaction Round
Series D -
Proceeds Purposes
Proceeds purposes were not disclosed. -
M&A Terms
-
Venture Investor
Novartis BioVenture Fund
